CFO Keith Vendola departs; Brian Burkavage appointed Chief Accounting Officer

IO Biotech, Inc.

Keith Vendola terminated as CFO by mutual agreement effective May 9, 2022; no disagreement with company or board.
CEO Mai-Britt Zocca will serve as Principal Financial Officer until CAO appointment.
Brian Burkavage, previously VP of Finance, appointed Chief Accounting Officer effective May 12, 2022.
Burkavage was Controller at Passage BIO (2020-2021) and Director of FP&A at Aclaris Therapeutics (2017-2020).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brian Burkavage

Chief Accounting Officer

IOBTQ · IO Biotech, Inc.

Effective: 2022-05-12
Filed: May 13, 2022, 7:59 PM ET

On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.

Departed

Keith Vendola

Chief Financial Officer

IOBTQ · IO Biotech, Inc.

Effective: 2022-05-09
Filed: May 13, 2022, 7:59 PM ET

On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Burkavage was appointed as Chief Accounting Officer at IO Biotech, Inc..

Action: appointed
Role: Chief Accounting Officer

Exact text from the filing

On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Vendola was terminated as Chief Financial Officer at IO Biotech, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.

View on SEC.gov

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-150146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.